Pivotal trial of Abivax chronic HBV vaccines under way

 

Published on February 26th, 2015

Abivax SAS dosed the first patient in a pivotal phase IIb/III trial of ABX203, a therapeutic vaccine it is testing against hepatitis B virus (HBV) e-antigen-negative active chronic HBV. The Paris-based company, testing whether it can ratchet up viral control for longer periods than current treatments ahead of Asian regulatory filings, expects results of the study in the third quarter of 2016. 

 

To read more, click here.

 

Press contacts

Caroline Carmagnol 

abivax@alizerp.com

+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65

 Standard: +33 1 53 83 08 41

More articles in French

Click here